LivaNova 3Q 2026: Revenue $393.15M, Net income $34.29M, EPS $0.11— 10-Q Summary

What happened

LivaNova reported third-quarter 2026 revenue of $393.15 million, up 9.9% year over year, and net income of $34.29 million, up 28%. Diluted earnings per share, or profit allocated to each share, fell to $0.11 from $0.49 a year earlier.

Confirmed

Global impact / market context

Revenue and net income growth indicate stronger sales and overall profit, but the sharp fall in earnings per share shows that profit attributable to each share moved differently. For investors, this contrast makes the drivers of share-level earnings important to assess alongside business growth.

Analyst inference

Both cardiopulmonary and neuromodulation revenue grew, with the article citing demand, sales volume and favorable pricing. Those gains could support revenue, while persistent supply constraints could limit product availability; the summary says production and distribution were not materially affected.

Analyst inference

What to watch

1. Check whether cardiopulmonary and neuromodulation sales continue growing, since the article links recent gains to consumables demand, Essenz sales, higher volume and favorable pricing. Analyst inference
2. Watch whether supply constraints begin materially affecting raw materials, production or distribution; the article says they have not materially affected these areas so far. Analyst inference
3. Compare future diluted earnings per share with net income growth to see whether the gap narrows or persists; the article reports $0.11 versus $0.49 year over year. Analyst inference

Evidence

• Original source link unavailable